The relationship between high-density lipoprotein cholesterol and coronary collateral circulation in patients with coronary artery disease

Journal of Investigative Medicine

Volumn 60, Issue 5, 2012, Pages 808-812

  Kadi, Hasan ^a   Ozyurt, Huseyin ^a   Ceyhan, Koksal ^a   Koc, Fatih ^a   Celik, Atac ^a   Burucu, Turgay ^a  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

Collateral circulation; Coronary artery disease; High density lipoprotein

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ANGIOCARDIOGRAPHY; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CHOLESTEROL, HDL; COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84860805063     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31824e980c     Document Type: Conference Paper

References (37)

1. Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res. 2006;99:1031-1043. (Pubitemid 44729927)
2. Tall AR, Yvan-Charvet L, Terasaka N, et al. HDL, ABC transporters, and cholesterol efflux: Implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365-375. (Pubitemid 351598023)
3. Miller NE, Thelle DS, Forde OH, et al. The Tromsø heart-study. High-density lipoprotein and coronary heart disease: A prospective case control study. Lancet. 1977;1:965-968.
4. Abbott RD, Wilson PW, Kannel WB, et al. High-density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1998;8:207-211.
5. Rubins HB, Schectman G, Wilt TJ, et al. Distribution of lipid phenotypes in community-living men with coronary heart disease. High prevalence of isolated low levels of high-density lipoprotein cholesterol. Arch Intern Med. 1992;152:2412-2416.
6. Gordon DJ, Rifkind BM. High-density lipoproteinVthe clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316. (Pubitemid 19267219)
7. Rossi F, Bertone C, Montanile F, et al. HDL cholesterol is a strong determinant of endothelial progenitor cells in hypercholesterolemic subjects. Microvasc Res. 2010;80:274-279.
8. Baker PW, Rye KA, Gamble JR, et al. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res. 2000;41:1261-1267. (Pubitemid 30666892)
9. Cocherill GW, Rye KA, Gamgle JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-1994.
10. Hessler JR, Robertson AL Jr, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 1979;32:213-229. (Pubitemid 9129780)
11. Sue I, Escargueil-Blane I, Troly M, et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol. 1997;17:2158-2166. (Pubitemid 28057117)
12. Pohl T, Seiler C, Billinger M, et al. Frequency distribution of collateral flow and factors influencing collateral channel development: Functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol. 2001;38:1872-1878. (Pubitemid 33116557)
13. Ceyhan K, Kadi H, Celik A, et al. Angiotensin-converting enzyme DD polymorphism is associated with poor coronary collateral circulation in patients with coronary artery disease. J Investig Med. 2012;60:49-55.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of The third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. Rentrop KP, Cohen M, Blanke H, et al. Changes in collateral filling immediately after controlled coronary artery occlusion by an angioplasty baloon in human. J Am Coll Cardiol. 1985;5:587-592. (Pubitemid 15141963)
16. Baroldi G, Montero O, Scomazzoni G. Coronary circulation in the normal and the pathological heart. Circ Res. 1956;4:223-229.
17. Elayda MA, Mather VS, Hall RJ, et al. Collateral circulation in coronary artery disease. Am J Cardiol. 1985;55:58-60. (Pubitemid 15152522)
18. Schwartz H, Leiboff RH, Bren GB, et al. Temporal evolution of the human coronary collateral circulation after myocardial infarction. J Am Coll Cardiol. 1984;4:1088-1093. (Pubitemid 15184183)
19. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 1994;94:2036-2044. (Pubitemid 24348244)
20. Guzman RJ, Abe K, Zarins CK. Flow-induced arterial enlargement is inhibited by suppression of nitric oxide synthase activity in vivo. Surgery. 1997;122:273-279.
21. Schneeweis C, Gräfe M, Bungenstock A, et al. Chronic CRP-exposure inhibits VEGF-induced endothelial cell migration. J Atheroscler Thromb. 2010;17:203-212.
22. Levkau B, Hermann S, Theilmeier G, et al. High-density lipoprotein stimulates myocardial perfusion in vivo. Circulation. 2004;110: 3355-3359. (Pubitemid 39557499)
23. Bisoendial RJ, Hovingh GK, Levels JHM, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944-2948. (Pubitemid 36736637)
24. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402. (Pubitemid 34263266)
25. Higashi Y, Matsuoka H, Umei H, et al. Endothelial function in subjects with isolated low HDL cholesterol: Role of nitric oxide and circulating progenitor cells. Am J Physiol Endocrinol Metab. 2010;298:E202-E209.
26. Gulec S, Ozdemir AO, Maradit-Kremers H, et al. Elevated levels of C-reactive protein are associated with impaired coronary collateral development. Eur J Clin Invest. 2006;36:369-375. (Pubitemid 43742693)
27. Kerner A, Gruberg L, Goldberg A, et al. Relation of C-reactive protein to coronary collaterals in patients with stable angina pectoris and coronary artery disease. Am J Cardiol. 2007;99:509-512. (Pubitemid 46215557)
28. Kadi H, Ceyhan K, Karayakali M, et al. The relationship between coronary collateral circulation and blood high-sensitivity C-reactive protein levels. Turk Kardiyol Dern Ars. 2011;39:23-28.
29. Wadham C, Albanese N, Roberts J, et al. High-density lipoproteins neutralize C-reactive protein inflammatory activity. Circulation. 2004;109:2116-2122. (Pubitemid 38620221)
30. Park SH, Park JH, Kang JS, et al. Involvement of transcription factors in plasma HDL protection against TNF-alphaYinduced vascular cell adhesion molecule expression. Int J Biochem Cell Bio. 2003;35:168-182. (Pubitemid 35441274)
31. Calabresi L, Franceschini G, Sirtori CR, et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun. 1997;238:61-65. (Pubitemid 27453274)
32. Calabresi L, Gomaraschi M, Villa B, et al. Elevated cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:656-661. (Pubitemid 34408749)
33. Nishikawa H, Miura S, Zhang B, et al. Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coron Artery Dis. 2002;13:377-381. (Pubitemid 36106246)
34. Pourati I, Kimmelstiel C, Rand W, et al. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J. 2003;146:876-881. (Pubitemid 37378578)
35. Zbinden S, Brunner N, Wustmann K, et al. Effect of statin treatment on coronary collateral flow in patients with coronary artery disease. Heart. 2004;90:448-459.
36. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, et al. ACTFAST investigators: Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J. 2007;153:881-888.
37. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J Am Coll Cardiol. 2007;49:290-297. (Pubitemid 46110954)